Top Suppliers:I want be here
Related CAS#:
1517872-69-3 1496517-17-9
1785422-27-6 1543241-49-1
1499150-19-4 1416346-75-2
1541466-11-8 1539198-75-8
1391310-19-2 1502622-04-9

186826-86-8

186826-86-8 structure
186826-86-8 structure
  • Name: Moxifloxacin HCl
  • Chemical Name: moxifloxacin hydrochloride
  • CAS Number: 186826-86-8
  • Molecular Formula: C21H25ClFN3O4
  • Molecular Weight: 437.892
  • Catalog: API Synthetic anti-infective drugs Quinolone
  • Create Date: 2018-02-05 08:00:00
  • Modify Date: 2026-07-03 10:54:59
  • Moxifloxacin (Hydrochloride) is a synthetic fluoroquinolone antibiotic agent.Target: AntibacterialMoxifloxacin is an extended-spectrum fluoroquinolone which has improved coverage against gram-positive cocci and atypical pathogens compared with older fluoroquinolone agents, while retaining good activity against gram-negative bacteria. The antibacterial spectrum of moxifloxacin includes all major upper and lower respiratory tract pathogens; it is one of the most active fluoroquinolones against pneumococci, including penicillin- and macrolide-resistant strains [1]. Moxifloxacin has limited phototoxic potential. In clinical trials, moxifloxacin had clinical success rates of 88-97% and bacteriologic eradication rates of 90-97%. Moxifloxacin is a safe and effective antimicrobial that will be useful for treating acute sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia [2]. Moxifloxacin possibly stimulates lipid peroxidation and enhances phagocytosis, as depicted by MDA production and survival prolongation, without being toxic as depicted by white blood cell count [3]. Clinical indications: Abdominal abscess; Acute bronchitis; Acute sinusitis; Bacterial infectionToxicity: Symptoms of overdose include CNS and gastrointestinal effects such as decreased activity, somnolence, tremor, convulsions, vomiting, and diarrhea. The minimal lethal intravenous dose in mice and rats is 100 mg/kg.
Name moxifloxacin hydrochloride
Synonyms 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridine-6-yl]-4-oxo-3-quinolinecarboxylic acid hydrochloride
Moxifloxacin (BAY9) HCl
Moxifioxacin hydrochloride
3-Quinolinecboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-Methoxy-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, Monohydrochloride, (4aS-cis)
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecboxylic AcidMonohydrochloride
Moxifloxacin
1-Cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride (1:1)
Moxifloxacin hydrochloride Solution, 1000ppm
Moxiflaxacin HCL
Moxifloxacin Hydrochloride (200 mg)
Moxifloxacin and intermediates
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecboxylic acid hydrochloride (1:1)
1-cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydropyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride
acide 1-cyclopropyl-6-fluoro-8-méthoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoléine-3-carboxylique chlorhydrate
Moxifloxacin：Moxifloxacin HCl
3-Quinolinecboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7- [(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-,monohydrochloride
4-dihydroquinoline-3-cboxylic acid hydrochloride
Moxifloxacin hydrochloride, (HPLC)
MoxifL
BAY9 HCl
Nafenac (CAS 78-8) and Moxifloxacin hydrochloride
Moxifloxacin Hyderochlodire
Moxifloxacin D4 HydrochlorideQ: What is Moxifloxacin D4 Hydrochloride Q: What is the CAS Number of Moxifloxacin D4 Hydrochloride Q: What is the storage condition of Moxifloxacin D4 Hydrochloride
Actura
1-cyclopropyl-7-(S,S)-2,8-diazabicyclo(4.3.0)-non-8-yl-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinoline carboxylic acid hydrochloride
Moxifloxacin hydrochloride solution in Methanol, 1000μg/mL
1-cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride
MOXIFLOXACIN HCL
1-Cyclopropyl-6-fluoro-7-((4aS,7aS)-hexahydro-1H-pyrrolo[3,4-b]pyridin-6(2H)-yl)-8-Methoxy-4-oxo-1,4-dihydroquinoline-3-cboxylic acid hydrochloride
moxifloxacin for peak identification(Y0000717)Q: What is moxifloxacin for peak identification(Y0000717) Q: What is the CAS Number of moxifloxacin for peak identification(Y0000717)
Moxiflocacin hydrochloride
Moxifloxacin hydrochloride CRS
1-Cyclopropyl-6-fluoro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic Acid Hydrochloride
C15338000 Moxifloxacin hydrochloride
AVELOX; AVALOX
Moxifloxacin HCl 1-Cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydro-6H- pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3- cboxylic acid hydrochloride
Actira
Moxifloxacin HCl (BAY9)
(1's,6's)-1-cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-cboxylic acid hydrochloride
1-Cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid hydrochloride (1:1)
1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo-[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid hydrochloride
1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO- 8-METHOXY-7- [(4AS,7AS)-OCTAHYDRO-6H-PYRROLO[3,4-B]PYRIDIN-6-YL]-4-OXO-3-QUINOLINECBOXYLIC ACID HYDROCHLORIDE
Moxifloxacin (Hydrochloride)
Moxifloxacin Hydrochloride 1
Moxifloxacin HydrochlorideQ: What is Moxifloxacin Hydrochloride Q: What is the CAS Number of Moxifloxacin Hydrochloride Q: What is the storage condition of Moxifloxacin Hydrochloride
Avelox
1-Cyclopropyl-6-fluoro-8-Methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-cboxylic acid hydrochloride
Avalox
oxacin hydrochL
Moxifloxacin hydrochloride //BP
ACTIRA
BAY-12-8039
Moxifloxacinehydrochloride
3-quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, monohydrochloride
1-cyclopropyl-6-fluoro-8-methoxy-7-((4aS,7aS)-octahydropyrrolo[3,4-b]pyridin-6-yl)-4-oxo-1,4-dihydroquinoline-3-cboxylic acid hydrochloride
AVALOX
2,4-Imidazolidinedione,5-(3-bromophenyl)-11-methyl
Moxifloxacin Hydrochloride Tablets
Avelox,Avalox
Vigamox
Moxifloxacin Hydrochloride IP/BP
Moxifloxacin Hydrochlorideand
Moxifloxacin hydrochloride hcl
Moxifloxacin hydrochloride, >=
Moxifloxacin HCl (Monohydrate)
Moxifloxacin hydrochloride, 10 mM in DMSO
MoxifloxacineHCl
Octegra
1-Cyclopropyl-6-fluor-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydrochinolin-3-carbonsäurehydrochlorid
MOXIFLOXACIN HYDROCHLORIDE
7-[(4aS,7aS)-octahydro-1H-pyrrolo[3,4-b]pyridin-6- yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-di hydroquinoline-3-cboxylic acid hydrochloride
PROFLOX
Izilox
1-CYCLOPROPYL-7-[(S,S)-2,8-DIAZA-BICYCLO[4.3.0]NON-8-YL]-6-FLUORO-8-METHOXY-1,4-DIHYDRO-4-OXO-3-QUINOLINE CBOXYLIC ACID HYDROCHLORIDE
3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrochloride (1:1)
MFCD00949117
Moxifloxacin Hcl MH
Moxifloxacin hydrochloride
(1'S,6'S)-1-cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-(1,4-dihydroquinoline)-3-carboxylic acid hydrochloride salt
Proflox
Moxifloxacin hydrochlorid
Moxifloxacin Hydrochloride ABCDEFGHJKL
Description Moxifloxacin (Hydrochloride) is a synthetic fluoroquinolone antibiotic agent.Target: AntibacterialMoxifloxacin is an extended-spectrum fluoroquinolone which has improved coverage against gram-positive cocci and atypical pathogens compared with older fluoroquinolone agents, while retaining good activity against gram-negative bacteria. The antibacterial spectrum of moxifloxacin includes all major upper and lower respiratory tract pathogens; it is one of the most active fluoroquinolones against pneumococci, including penicillin- and macrolide-resistant strains [1]. Moxifloxacin has limited phototoxic potential. In clinical trials, moxifloxacin had clinical success rates of 88-97% and bacteriologic eradication rates of 90-97%. Moxifloxacin is a safe and effective antimicrobial that will be useful for treating acute sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia [2]. Moxifloxacin possibly stimulates lipid peroxidation and enhances phagocytosis, as depicted by MDA production and survival prolongation, without being toxic as depicted by white blood cell count [3]. Clinical indications: Abdominal abscess; Acute bronchitis; Acute sinusitis; Bacterial infectionToxicity: Symptoms of overdose include CNS and gastrointestinal effects such as decreased activity, somnolence, tremor, convulsions, vomiting, and diarrhea. The minimal lethal intravenous dose in mice and rats is 100 mg/kg.
Related Catalog
References

[1]. Balfour, J.A. and H.M. Lamb, Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs, 2000. 59(1): p. 115-39.

[2]. Culley, C.M., et al., Moxifloxacin: clinical efficacy and safety. Am J Health Syst Pharm, 2001. 58(5): p. 379-88.

[3]. Ioannidis, O., et al., Effect of moxifloxacin on the survival, lipid peroxidation and inflammation of immunosuppressed rats with soft tissue infection from Stenotrophomonas maltophilia. Microbiol Immunol, 2013.
Boiling Point 636.4ºC at 760 mmHg
Molecular Formula C21H25ClFN3O4
Molecular Weight 437.892
Flash Point 338.7ºC
Exact Mass 437.151764
PSA 83.80000
LogP 3.56630
Vapour Pressure 4.56E-17mmHg at 25°C
Storage condition 2-8°C
Hazard Codes Xi
RIDADR NONH for all modes of transport
RTECS VB1983750
HS Code 2933499090
151096-09-2 structure

151096-09-2

~74%

186826-86-8 structure

186826-86-8

Literature: CIPLA LIMITED; CURTIS, Philip, Anthony Patent: WO2008/59223 A2, 2008 ; Location in patent: Page/Page column 15-16 ;
139693-52-0 structure

139693-52-0

151213-40-0 structure

151213-40-0

~%

186826-86-8 structure

186826-86-8

Literature: WO2010/52726 A1, ; Page/Page column 5; 6 ;
496919-99-4 structure

496919-99-4

151213-40-0 structure

151213-40-0

~73%

186826-86-8 structure

186826-86-8

Literature: CIPLA LIMITED; CURTIS, Philip, Anthony Patent: WO2008/59223 A2, 2008 ; Location in patent: Page/Page column 13-14 ;
192927-63-2 structure

192927-63-2

~%

186826-86-8 structure

186826-86-8

Literature: WO2007/10555 A2, ; Page/Page column 15 ;
112811-72-0 structure

112811-72-0

~%

186826-86-8 structure

186826-86-8

Literature: EP2551268 A1, ;
151213-40-0 structure

151213-40-0

~%

186826-86-8 structure

186826-86-8

Literature: EP2551268 A1, ;
112811-70-8 structure

112811-70-8

~%

186826-86-8 structure

186826-86-8

Literature: Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, , vol. 121, p. 254 - 258
151213-39-7 structure

151213-39-7

~%

186826-86-8 structure

186826-86-8

Literature: Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, , vol. 121, p. 254 - 258
112811-72-0 structure

112811-72-0

151213-40-0 structure

151213-40-0

~%

186826-86-8 structure

186826-86-8

Literature: Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, , vol. 121, p. 254 - 258
HS Code 2933990090
Summary 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

Chemsrc provides CAS#:186826-86-8 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 186826-86-8 | Chemsrc address: https://m.chemsrc.com/en/baike/330799.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2026 ChemSrc All Rights Reserved